Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

K 8

Next Previous
X
Search
Drug Profile

K 8

Alternative Names: Inflammasome inhibitor-Inflammasome Therapeutics; K-8; Kamuvudine-8; SOM-401

Latest Information Update: 15 Nov 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Inflammasome Therapeutics
  • Class Eye disorder therapies
  • Mechanism of Action NLRC4 protein inhibitors; NLRP3 protein inhibitors; Nucleoside reverse transcriptase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Diabetic macular oedema; Dry macular degeneration

Most Recent Events

  • 20 Jun 2024 Inflammasome Therapeutics completes a phase-I trial in Diabetic macular oedema in USA (Intravitreous), (NCT05699759),
  • 05 Mar 2024 Phase-I clinical trials in Dry macular degeneration in USA (Intravitreous) (NCT06164587)
  • 04 Jan 2024 Phase-I clinical trials in Diabetic macular oedema in USA (Intravitreous) (NCT05699759),

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top